Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 5,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Agent Clear all

Conditions: B-Cell Lymphoma, Non-Hodgkin Lymphoma
Interventions: Glofitamab, Obinutuzumab (G), Rituximab (R), Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania

Conditions: KRAS Mutant Solid Tumors
Interventions: TLN-372, TLN-372 in combination with cetuximab, TLN-372 in combination with pembrolizumab; Drug
Lead sponsor: Treeline Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 6
States / cities: Birmingham, Alabama • Boston, Massachusetts • Grand Rapids, Michigan + 3 more

Conditions: Colorectal Cancer
Interventions: cetuximab, fluorouracil, neoadjuvant therapy, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Acquired Immunodeficiency Syndrome, Healthy Volunteers, HIV/AIDS, HIV Diarrhea, Human Immunodeficiency Virus
Interventions: Crofelemer delayed-release tablets 125mg; Drug
Lead sponsor: Napo Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Tustin, California • Stratford, Connecticut • Springfield, Massachusetts

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 3,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Emtricitabine / Tenofovir; Drug
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Pancreatic Cancer
Interventions: Chemoradiation (Radiation Therapy), Vorinostat; Radiation · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Periodontal Disease
Interventions: lidocaine and prilocaine; Drug
Lead sponsor: Dentsply International; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Flucytosine, Fluconazole, Amphotericin B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: amifostine trihydrate, cisplatin, gemcitabine hydrochloride; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Lymphocytic Leukemia
Interventions: During Venetoclax; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Levocarnitine, Adefovir dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Foster City, California

Conditions: Vaginal Dysbiosis, Vaginal Disease, Molecular-bacterial Vaginosis
Interventions: Probiotic Group, Placebo Group; Dietary Supplement
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Cystic Fibrosis
Interventions: VX-121, TEZ, VX-561, TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 12
States / cities: Los Angeles, California • Oakland, California • Lexington, Kentucky + 9 more

Conditions: Parkinson's Disease (PD)
Interventions: Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump, Percutaneous endoscopic gastrostomy tube, Jejunal extension tube; Drug · Device
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Port Charlotte, Florida • Round Rock, Texas

Conditions: Cardiovascular Disease
Interventions: EVARREST™ Fibrin Sealant Patch, Topical hemostat; Biological
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 9
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 6 more

Conditions: Hepatitis, Viral, Human, HIV Infections
Interventions: Testing, Education, & Counseling (TEC), Hepatitis Care Coordination (HCC); Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Rabies
Interventions: Chloroquine, Atovaquone and Proguanil, Doxycycline, Rabies Vaccine; Drug · Biological
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Acute Otitis Media
Interventions: amoxicillin/clavulanate postassium (Augmentin ES-600), azithromycin SR; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months to 48 Months
Enrollment: 902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 23
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Bellflower, California + 18 more

Conditions: Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
Interventions: XL184, temozolomide, Radiation Therapy; Drug · Radiation
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 8
States / cities: Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 5 more

Conditions: Advanced Parkinson's Disease
Interventions: Levodopa carbidopa intestinal gel (LCIG), Placebo Gel, Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube; Drug · Device
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 30 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 11
States / cities: Birmingham, Alabama • Fountain Valley, California • Oceanside, California + 8 more

Conditions: ECRB Tendinopathy
Interventions: Semiconductor Embedded Therapeutic Arm Sleeves, Placebo Arm Sleeves, Platelet-Rich Plasma with Adipose Stem Cell (PRP+ASC) Injections; Device · Other
Lead sponsor: INCREDIWEAR HOLDINGS, INC.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: AML With Monocytic Differentiation, CMML
Interventions: IO-202, IO-202 and Azacitidine, IO-202 and Azacitidine + Venetoclax; Biological
Lead sponsor: Immune-Onc Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 14
States / cities: Davis, California • Duarte, California • Irvine, California + 11 more

Conditions: Kidney Transplantation, Hepatitis C
Interventions: sofosbuvir/velpatasvir; Drug
Lead sponsor: Amit D Tevar, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

TLN-372 in Advanced KRAS Mutant Solid Tumors

Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

Defining the PrEP Care Continuum Among Recently Incarcerated Men at High-Risk for HIV Infection

Vorinostat Plus Radiation Therapy in Pancreatic Cancer

Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations

Feasibility of an Oral Intervention for Sexual Health in Transgender Men

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

The Fibrin Pad CV Phase III Study

HIV and Hepatitis Care Coordination in Methadone Treatment

Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.

A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections

Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

The Comparison of Semiconductor Embedded Therapeutic Arm Sleeves for the Treatment of ECRB Tendinopathy

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients